Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

Focus and Scope

The “Diabetes Mellitus” is a peer-reviewed research and clinical journal published bimonthly since 1998 under the auspices of Russian Association of Endocrinologists and Federal Endocrinology Research Centre (Moscow).

Its content focuses on original papers on clinical, experimental and academic studies, but also includes reviews, lectures, case reports and supplementary materials. General discourse of the journal is dedicated to the key aspects of diabetology, encompassing etiology, epidemiology and pathogenesis of diabetes mellitus, novel diagnostic and therapeutic methods, as well as prevention and management of acute and late complications of diabetes mellitus and associated conditions.

The intended primary audience of the journal is medical professionals (including diabetologists, endocrinologists, general practitioners, family physicians and pediatricians), scientists and academicians working in the area of endocrinology and diabetology.

From 2014 “Diabetes Mellitus” has become fully bilingual, now featuring full-text English versions of published materials, and adopted the Gold Open Access distribution model.

The current editorial board understanding of the journal’s unique mission  is as following (beyond ordinary task to provide access to the most relevant and accurate data in appropriate research field):

  • to facilitate the exchange of clinical experience and scientific data between Russian-speaking and international diabetology communities;
  • to inform Russian-speaking medical professionals about the relevant and high-quality evidence-based clinical data. 

 

Section Policies

Review

The journal publishes reviews of literature, including systematic reviews of clinical trials in different directions of diabetess mellitus and related areas.

The main purpose of a review manuscript should be a discussion of actual data or presentation the original author's view on a problem. It shouldn't be a simple enumeration of previously published data. Thus, the discussion is a mandatory part of the review manuscript (it can be isolated in a separate section or place systematically throughout the text).

Authors should indicate all the sources of primary information in the manuscript (names of the full-text and references databases, keywords and other search settings).

The manuscript of literature review should be structured into sections and contain graphic materials.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Original Studies

The journal accept manuscript containing results of international and local clinical and experimental studies, and meta-analyzes in the area of diabetology and related specialties.

The journal is welcome for manuscripts with human subjects studies results, as well as results of experimental studies in vitro and animal studies. Journal does not publish experimental and clinical studies of dietary supplements ("bioactive adds to food").

Editorial board will select for publication only manuscropts of clinical and experimental studies which were conducted in accordance with international biomedical ethics and deontology principles. Editorial board asks the authors to describe that presented study was conducted in accordance with international GCP standards: voluntary signing of an informed consent by all of participants; approval of the study protocol by the local ethics committee (the distinct name of ethics committee, the meeting date and protocol number should be indicate in a manuscript), etc.

The detailed study protocol should be presented in the manuscript. Authors should give so many details of a study protocol as need for it fully replaying. In the case of meta-analyze authors should describe in details the procedure of information search: names of databases, filters and keywords, as well as any additional search settings for primary sources collecting.

In compliance with the ethics policy editorial board asks authors to indicate the source of funding of their work (study preparation, writing and publishing the manuscript, etc.), and declare of apparent or potential conflicts of interests. Please note that the presence of obvious or potential conflict of interest (including the financial interest of the authors) or affiliation of any organization (public or private) with conduction of the research is not a reason for a manuscript rejection. Rather, it gives additional advantages of manuscript under evaluation by reviewers and will cause more interest and trust from readers.

Checked Open Submissions Checked Indexed Checked Peer Reviewed

Short Messages

The journal is looking for manuscripts with case reports in the area of diabetology and related specialties.

Potential topics for case reports are:

  • diagnosis - new or rare diabetes-related condition or unusual presentation of common condition, uncertain diagnosis situation, discussion of differential diagnoses, novel diagnostic procedures;
  • treatment - new treatments or established treatments in new situations, treatment of rare diabetes-related conditions, unique technical procedures, unexpected outcomes or effects from routine or rare procedures, adverse events or unanticipated events;
  • special circumstances - highly individualized treatments, complex situations, integration of multiple therapies, ethical challenges, learning from errors, findings that shed new light on the possible pathogenesis of a disease or an adverse effect.

The main purpose of a manuscript should be a clinical case presentation in view of diagnostic approach, ethical or management challenge, or highlights new aspects of pathogenesis, pharmacology or histopathology. Manuscript should discuss accumulated facts and also compare new data with previously proven information.

We recommend all authors to hold the manuscript structure and chronologize all the facts, report common information about the patient’s disease. In case your manuscript is devoted to treatment challenge, describe the medication, its indications and usage specifications also with any potential side effects. A summary of data on the topic may be also presented. Briefly summarize the background of this case report. Describe the patient characteristics (such as the relevant demographics — age, gender, ethnicity, occupation) and their presenting concerns with relevant details of related past interventions. Also, present the medical, family, and psychosocial history including lifestyle and genetic information, other pertinent co-morbidities and interventions (other therapies including self-care).

Data structure for a case report should include the following sections:

  • symptoms of the disorder;
  • physical examination focused on the important findings including results from testing;
  • diagnostic methods (including laboratory testing, imaging results, questionnaires, referral diagnostic information);
  • diagnostic challenges (such as limited ability to complete an evaluation, patient availability, cultural) and diagnostic reasoning including other diagnoses considered;
  • interventions (such as pharmacologic, surgical, preventive, lifestyle, self-care);
  • administration and intensity of the intervention (including dosage, strength, duration, frequency);
  • prognostic characteristics.

Please describe the strengths and limitations of this case report including case management, and the scientific and medical literature related to this case report. Discuss the rationale for your conclusions such as potential causation and the ways this case might be generalized to a larger population. Finally, what are the main findings of this case report and what are the 'take-away' messages?

Checked Open Submissions Checked Indexed Checked Peer Reviewed
 

Peer Review Process

A double-blind peer review method is mandatory for processing of all scientific manuscripts submitted to the editorial stuff of “Diabetes mellitus”. This implies that neither the reviewer is aware of the authorship of the manuscript, nor the author maintains any contact with the reviewer.

  1. Members of the editorial board and leading international experts in corresponding areas of life sciences, invited as independent readers, perform peer reviews (3 to 5 per manuscript). Editor-in-chief, deputy editor-in-chief or science editor choose experts for peer review. We use Publons to search and recognize our reviewers. We aim to limit the review process to 2 weeks, though in some cases the schedule may be adjusted at the reviewer’s request.
  2. Reviewer has an option to abnegate the assessment should any conflict of interests arise that may affect perception or interpretation of the manuscript. Upon the scrutiny, the reviewer is expected to present the editorial board with one of the following recommendations:
    • to accept the paper in its present state;
    • to invited the author to revise their manuscript to address specific concerns before final decision is reached;
    • that final decision be reached following further reviewing by another specialist;
    • to reject the manuscript outright.
  3. If the reviewer has recommended any refinements, the editorial staff would suggest the author either to implement the corrections, or to dispute them reasonably. Authors are kindly required to limit their revision to 2 months and resubmit the adapted manuscript within this period for final evaluation.
  4. We politely request that the editor be notified verbally or in writing should the author decide to refuse from publishing the manuscript. In case the author fails to do so within 3 months since receiving a copy of the initial review, the editorial board takes the manuscript off the register and notifies the author accordingly.
  5. If author and reviewers meet insoluble contradictions regarding revision of the manuscript, the editor-in-chief resolves the conflict by his own authority.
  6. The editorial board reaches final decision to reject a manuscript on the hearing according to reviewers’ recommendations, and duly notifies the authors of their decision via e-mail. The board does not accept previously rejected manuscripts for re-evaluation.
  7. Upon the decision to accept the manuscript for publishing, the editorial staff notifies the authors of the scheduled date of publication.
  8. Kindly note that positive review does not guarantee the acceptance, as final decision in all cases lies with the editorial board. By his authority, editor-in-chief rules final solution of every conflict.
  9. Original reviews of submitted manuscripts remain deposited permanently (not less than 5 years).
  10. Manuscript reviews are not published. Reviews can be sent to the Ministry of Education and Sciense of Russian Federation in case of query.

 

Publication Frequency

The regular issues of the journal publishes bimonthly, 6 times per year.

The journal publish supplemental issues with Russian national medical standarts for diabetes treatment and prevention every 2 years. 

Contents of Print and Online versions of the journal issues are different: the full set of article present in Online version, but the Print version contains only articles with Russian fulltext.

The Publish Ahead-of-Print section of the journal contains articles already have been accepted by Editorial Board but not copyedited and typesetted by Publisher.

 

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

 

Archiving

This journal utilizes the LOCKSS system to create a distributed archiving system among participating libraries and permits those libraries to create permanent archives of the journal for purposes of preservation and restoration. More...

 

Indexing

Articles in "Diabetes Mellitus" journal are indexed by several systems:

 

Publishing Standards and Ethics

The Ethic policy of "Diabetes Mellitus" journal is based on recomendations from international commettees:

  

 

Reporting standarts

The Diabetes Mellitus journal editorial team ask authors of reports of original research to present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable.

Review and professional publication articles should also be accurate and objective, and editorial opinion works should be clearly identified as such.

Data Access and Retention

Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

Authorship clarified

The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before the work is submitted.

The Publisher does not prescribe the kinds of contributions that warrant authorship. It is recommended that authors adhere to the guidelines for authorship that are applicable in their specific research field. In absence of specific guidelines it is recommended to adhere to the following guidelines (based on ICMJE guidelines):

All authors whose names appear on the submission:

  1. made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work AND
  2. drafted the work or revised it critically for important intellectual content AND
  3. approved the version to be published AND
  4. agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Anyone who contributed to the research or manuscript preparation, but is not an author, should be acknowledged with their permission.

Submissions by anyone other than one of the authors will not be considered.

Research Ethics and Patient Consent (Statement of Human and Animal Rights)

Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.

Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

Hazards for Human or Animal Subjects

If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript. If the work involves the use of animal or human subjects, the authors should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

When reporting experiments on animals, authors have to indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

Research involving human embryos, gametes, and stem cells

Manuscripts that report experiments involving the use of human embryos and gametes, human embryonic stem cells and related materials, and clinical applications of stem cells must include confirmation that all experiments were performed in accordance with relevant guidelines and regulations (See also Research involving human participants and/or animals)

The manuscript should include an ethics statement identifying the institutional and/or national research ethics committee (including the name of the ethics committee) approving the experiments and describing any relevant details. Authors should confirm that informed consent (See also Informed consent) was obtained from all recipients and/or donors of cells or tissues, where necessary, and describe the conditions of donation of materials for research, such as human embryos or gametes. Copies of approval and redacted consent documents may be requested by the Journal.

We encourage authors to follow the principles laid out in the 2016 ISSCR Guidelines for Stem Cell Research and Clinical Translation.

In deciding whether to publish papers describing modifications of the human germline, the Journal is guided by safety considerations, compliance with applicable regulations, as well as the status of the societal debate on the implications of such modifications for future generations. In case of concerns regarding a particular type of study the Journal may seek the advice from the Springer Nature Research Integrity Group.

The decision to publish a paper is the responsibility of the Editor-in-Chief of the Journal.

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

Conflicts of Interest

The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

Conflicts include the following:

  • Financial — funding and other payments, goods and services received or expected by the authors relating to the subject of the work or from an organization with an interest in the outcome of the work;
  • Affiliations — being employed by, on the advisory board for, or a member of an organization with an interest in the outcome of the work;
  • Intellectual property — patents or trademarks owned by someone or their organization;
  • Personal — friends, family, relationships, and other close personal connections;
  • Ideology — beliefs or activism, for example, political or religious, relevant to the work;
  • Academic — competitors or someone whose work is critiqued.

For more information on conflicts of interest, see the guidance from the ICMJE and WAME.

Funding and Acknowledgement of Sources

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/  

Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.

Plagiarism

Plagiarism takes many forms, from passing off another paper as the author(s) own paper, to copying or paraphrasing substantial parts of another(s) paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable. Only original works are acceptable for publication in "Diabetes Mellitus" journal. The journal does not allow any forms of plagiarism. Authors must not use the words, figures, or ideas of others without attribution. All sources must be cited at Diabetes mellitus journal take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. All the submitted articles are evaluated with plagiarism-checking software (Antiplagiat). Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgment, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to:

  • publishing an erratum or corrigendum (correction);
  • retracting the article;
  • taking up the matter with the head of department or dean of the author’s institution and/or relevant academic bodies or societies;
  • or taking appropriate legal action.

Also you can see ORI Avoiding Plagiarism, Self-plagiarism, and Other Questionable Writing Practices: A Guide to Ethical Writing

Duplicate Submission and Redundant Publication

Diabetes Mellitus journal consider only original content, i.e. articles that have not been previously published, including in a language other than English. Articles based on content previously made public only on a preprint server, institutional repository, or in a thesis will be considered.

Manuscripts submitted to Diabetes Mellitus journal must not be submitted elsewhere while under consideration and must be withdrawn before being submitted elsewhere. Authors whose articles are found to have been simultaneously submitted elsewhere may incur sanctions.

If authors have used their own previously published work, or work that is currently under review, as the basis for a submitted manuscript, they must cite the previous articles and indicate how their submitted manuscript differs from their previous work. Reuse of the authors’ own words outside the Methods should be attributed or quoted in the text. Reuse of the authors’ own figures or substantial amounts of wording may require permission from the copyright holder and the authors are responsible for obtaining this.

Diabetes Mellitus journal will consider extended versions of articles published at conferences provided this is declared in the cover letter, the previous version is clearly cited and discussed, there is significant new content, and any necessary permissions are obtained.

Redundant publication, the inappropriate division of study outcomes into more than one article (also known as salami slicing), may result in rejection or a request to merge submitted manuscripts, and the correction of published articles. Duplicate publication of the same, or a very similar, article may result in the retraction of the later article and the authors may incur sanctions.

Citation Manipulation

Authors whose submitted manuscripts are found to include citations whose primary purpose is to increase the number of citations to a given author’s work, or to articles published in a particular journal, may incur sanctions.

Editors and reviewers must not ask authors to include references merely to increase citations to their own or an associate’s work, to the journal, or to another journal they are associated with.

Fundamental errors in published works, Corrections and Retractions

When an author discovers a significant error or inaccuracy in his/her own published work, it is the authors obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper.

If the editor or the publisher learn from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper or provide evidence to the editor of the correctness of the original paper.

When errors are identified in published articles, the publisher will consider what action is required and may consult the editors and the authors’ institution(s). 

Errors by the authors may be corrected by a corrigendum, and errors by the publisher — by an erratum (see more).

If there are errors that significantly affect the conclusions or there is evidence of misconduct, this may require retraction or an expression of concern following the COPE Retraction Guidelines. All authors will be asked to agree to the content of the appropriate notice.

Sanctions

If Diabetes mellitus journal becomes aware of breaches of our publication ethics policies, the following sanctions may be applied:

  • Rejection of the manuscript and any other manuscripts submitted by the author(s).
  • Not allowing submission for 1–3 years.
  • Prohibition from acting as an editor or reviewer.

Diabetes mellitus journal may apply additional sanctions for severe ethical violations.

 

Publication Fee

Publication in "Diabetes Mellitus" journal is free for all authors.

The "Diabetes Mellitus" journal charge no publication fees from authors - including those of peer-review management (except cases with Fast-Track option activation), manuscript processing, journal production, Open-Access, online hosting and archiving.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies